Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLucid Diagnostics Inc

Lucid Diagnostics Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.4451 USD 0.04 ( 8.83%)
Last update at 2026-11-04T21:08:00Z
VOLUME
3541677
Market Cap
47.02M

Momentum Score

…

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.41
Low
0.48
High
52 Week Price Range
0.63
Low
1.85
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Lucid Diagnostics Inc is a molecular diagnostics company developing point-of-care tests for infectious respiratory diseases. Long-term growth drivers include expanding demand for decentralized molecular testing, successful regulatory approvals, and commercial adoption of its consumable-based platform; investors may find the company attractive because it appears positioned to address a large respiratory diagnostics market with recurring reagent sales.

Material risks include limited commercial track record, intense competition from established diagnostics firms, regulatory and reimbursement uncertainty, and potential need for additional financing to scale.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.41
Dividend Yield
-
Revenue TTM
2.98M
Revenue Per Share
0.07
Gross Profit TTM
-3.24M
Debt / Equity
-6.60
ROE
-255.60%
Net Debt
-3.64M
ROCE
2659.61%
Diluted EPS TTM
-1.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -56.17M -28.08M -8.28M -4.42M -
Net income -56.17M -28.74M -8.28M -4.42M -
Selling general administrative 23.68M 12.78M 2.84M 0.96M -
Selling and marketing expenses 16.13M 5.26M - - -
Gross profit -3.24M -0.09M - - -
Reconciled depreciation 1.94M 0.00M - - -
Ebit -56.17M -27.42M -8.28M -4.42M -1.69M
Ebitda -54.23M -27.41M -8.28M -4.42M -
Depreciation and amortization 1.94M 0.00M - - -
Operating income -56.17M -27.42M -8.28M -4.42M -
Other operating expenses 56.55M 27.92M 8.28M 4.42M -
Interest expense 0.00M 0.66M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M -
Net interest income 0.00M -0.66M - - -
Income tax expense - 0.66M - - -
Total revenue 0.38M 0.50M 0.00M 0.00M -
Total operating expenses 52.93M 27.33M 8.28M 4.42M -
Cost of revenue 3.61M 0.58M - - -
Total other income expense net - -0.66M - - -
Net income from continuing ops -56.17M -28.08M -8.28M -4.42M -
Net income applicable to common shares -56.17M -28.08M -8.28M -4.42M -1.69M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 27.27M 32.51M 59.00M 2.19M 1.03M
Intangible assets 1.42M 3.44M - - -
Other current assets 3.13M 1.75M 2.95M 0.49M 0.23M
Total liab 29.58M 9.46M 4.26M 15.71M 6.34M
Total stockholder equity -2.31M 23.05M 54.74M -13.52M -5.31M
Other current liab 13.18M 6.41M 2.77M 13.66M 5.54M
Common stock 0.04M 0.04M 0.04M 0.01M 0.01M
Capital stock 18.67M 0.04M 0.04M 0.01M 0.01M
Retained earnings -150.74M -98.08M -41.90M -13.83M -5.55M
Other assets 0.00M 1.11M 0.72M 0.76M 0.64M
Cash 18.90M 22.47M 53.66M 0.11M 0.16M
Total current liabilities 29.38M 8.43M 4.26M 15.71M 6.34M
Net debt -3.64M -20.48M -53.66M -0.11M -0.16M
Short term debt 15.06M 0.96M - - -
Short long term debt 13.95M - - - -
Short long term debt total 15.26M 2.00M - - -
Other stockholder equity 18754.76M 121.08M 96.61M 0.29M 0.22M
Property plant equipment - 1.59M 0.97M - -
Total current assets 22.07M 24.36M 57.30M 1.44M 0.39M
Net tangible assets - 19.60M -24.13M -13.52M -5.31M
Net receivables 0.04M 0.02M 0.20M - -
Inventory 0.28M 0.11M 0.49M 0.83M 0.00M
Accounts payable 1.15M 1.06M 1.49M 2.06M 0.80M
Accumulated other comprehensive income -18625.00M - - - -
Common stock total equity - 0.04M - - -
Retained earnings total equity - -98.08M - - -
Non currrent assets other 1.13M 1.11M 0.72M 0.76M 0.64M
Non current assets total 5.20M 8.15M 1.70M 0.76M 0.64M
Capital lease obligations 1.30M 2.00M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.11M -0.86M 0.00M 0.00M -
Change to liabilities 7.56M -0.67M 1.15M 0.30M 0.75M
Total cashflows from investing activities -4.11M -0.86M -0.86M -0.86M -0.86M
Net borrowings - 7.74M 5.58M 2.50M 0.18M
Total cash from financing activities 2.61M 72.08M 5.58M 2.50M 0.20M
Change to operating activities 9.17M 1.67M 1.44M 1.58M 0.33M
Net income -56.17M -28.08M -8.28M -4.42M -1.69M
Change in cash -31.18M 53.55M -0.05M 0.14M 0.03M
Begin period cash flow 53.66M 0.11M 0.16M 0.02M -
End period cash flow 22.47M 53.66M 0.11M 0.16M 0.02M
Total cash from operating activities -29.68M -17.67M -5.63M -2.36M -0.17M
Issuance of capital stock 1.81M 70.00M - - -
Depreciation 1.94M 0.00M 0.00M 0.00M 0.00M
Other cashflows from investing activities -0.91M - - - -
Change to account receivables 0.18M -0.20M -0.20M -0.20M -0.20M
Sale purchase of stock 109.00M - - - -
Other cashflows from financing activities -108.20M 2.08M 5.58M 2.50M -5.66M
Change to netincome 13.86M 9.60M 0.07M 0.17M 0.44M
Capital expenditures 0.91M 0.86M 0.86M 0.86M 0.86M
Change receivables 0.18M - - - -
Cash flows other operating 2.95M - - - -
Cash and cash equivalents changes -31.18M - - - -
Change in working capital 8.91M 0.81M 2.59M 1.89M -
Stock based compensation 14.99M 9.60M 0.07M 0.17M -
Other non cash items 0.65M 0.47M 10.91M - -
Free cash flow -30.59M -18.53M -5.63M -2.36M -

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LUCD
Lucid Diagnostics Inc		 0.04
8.83%		 0.45 - - 16.07 2.16 22.25 -1.09
ABT
Abbott Laboratories		 6.11
5.58%		 115.51 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 6.08
6.15%		 104.96 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 29.10
9.37%		 339.65 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 48.37 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Lucid Diagnostics Inc

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

360 Madison Avenue, New York, NY, United States, 10017

917 813 1828

https://www.luciddx.com

70

Name Title Year Born
Dr. Lishan Aklog M.D. Chairman & CEO 1966
Mr. Dennis M. McGrath CPA CFO, Pres & Sec. 1957
Dr. Sanford D. Markowitz M.D., Ph.D. Cofounder & Strategic Advisor, Member of the Medical Advisor Board NA
Dr. Joseph Willis M.D. Cofounder, Strategic Advisor & Member of Medical Advisory Board NA
Dr. Amitabh Chak M.D. Cofounder, Strategic Advisor & Member of Medical Advisory Board NA
Mr. Shaun M. O'Neill M.B.A. Exec. VP & COO 1982
Richard D. Yazbeck Chief Technology Officer NA
Dr. Suman M. Verma M.D., Ph.D. Chief Scientific Officer NA
Mr. Adrian K. Miller VP of Investor Relations NA
Dr. Brian J. deGuzman M.D. Chief Compliance Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…